The rise of compounded GLP-1 drugs offers access for those needing treatment amid shortages but raises regulatory and legal concerns for established pharmaceutical companies.
Scott Brunner highlighted that compounding isn’t merely exploiting a loophole; he asserts that it is an intentional policy set forth by the FDA to meet specific patient needs.
Collection
[
|
...
]